|
Valuación de DCF Vistagen Therapeutics, Inc. (VTGN)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
VistaGen Therapeutics, Inc. (VTGN) Bundle
¡Descubra el verdadero potencial de Vistagen Therapeutics, Inc. (VTGN) con nuestra calculadora DCF avanzada! Ajuste los supuestos clave, explore varios escenarios y evalúe cómo los cambios influyen en la valoración de Vistagen, todo dentro de una plantilla de Excel conveniente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 1.1 | 1.1 | -.2 | 1.1 | .5 | .3 | .1 | .1 | .0 |
| Revenue Growth, % | 0 | 0 | 1.78 | -120.47 | -568.72 | -49.55 | -49.55 | -49.55 | -49.55 | -49.55 |
| EBITDA | -20.7 | -17.4 | -47.0 | -58.7 | -32.5 | -.1 | -.1 | .0 | .0 | .0 |
| EBITDA, % | 100 | -1600.83 | -4242.75 | 25874.89 | -3050.09 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .1 | .5 | .7 | .5 | .6 | .2 | .1 | .0 | .0 | .0 |
| Depreciation, % | 100 | 43.84 | 64.13 | -234.36 | 53.38 | 32.27 | 32.27 | 32.27 | 32.27 | 32.27 |
| EBIT | -20.8 | -17.9 | -47.8 | -59.3 | -33.0 | -.1 | -.1 | .0 | .0 | .0 |
| EBIT, % | 100 | -1644.66 | -4306.88 | 26109.25 | -3103.48 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 1.4 | 103.1 | 68.1 | 16.6 | 119.2 | .3 | .2 | .1 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .1 | .1 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 3.73 | 0 | 0 | 0 | 20.75 | 20.75 | 20.75 | 20.75 | 20.75 |
| Inventories | .0 | .9 | 2.5 | -.7 | .0 | .4 | .2 | .1 | .1 | .0 |
| Inventories, % | 100 | 86.48 | 221.21 | 324.05 | 0 | 77.3 | 77.3 | 77.3 | 77.3 | 77.3 |
| Accounts Payable | 1.8 | .8 | 2.8 | 2.5 | 1.5 | .3 | .1 | .1 | .0 | .0 |
| Accounts Payable, % | 100 | 76.94 | 248.77 | -1089.43 | 145.39 | 55.39 | 55.39 | 55.39 | 55.39 | 55.39 |
| Capital Expenditure | .0 | -.3 | -.2 | -.2 | -.1 | -.1 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | -25.28 | -18.07 | 93.39 | -5.73 | -9.82 | -9.82 | -9.82 | -9.82 | -9.82 |
| Tax Rate, % | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 | -0.01362491 |
| EBITAT | -20.8 | -17.9 | -47.8 | -59.3 | -33.0 | -.1 | -.1 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -18.8 | -19.7 | -46.8 | -56.1 | -34.2 | -1.8 | .1 | .1 | .0 | .0 |
| WACC, % | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 | 7.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -117 | |||||||||
| Equity Value | 116 | |||||||||
| Diluted Shares Outstanding, MM | 19 | |||||||||
| Equity Value Per Share | 5.98 |
What You Will Get
- Pre-Filled Financial Model: VistaGen’s actual data facilitates accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, WACC, and other critical factors.
- Instant Calculations: Automatic updates provide real-time results as you make adjustments.
- Investor-Ready Template: A polished Excel file crafted for professional-level valuation.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for comprehensive forecasts.
Key Features
- Comprehensive VTGN Data: Pre-filled with VistaGen Therapeutics’ historical performance metrics and future projections.
- Customizable Input Parameters: Modify revenue growth rates, profit margins, discount rates, tax assumptions, and capital investments.
- Adaptive Valuation Framework: Real-time updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation possibilities.
- Intuitive Interface: Clean, organized, and tailored for both industry experts and newcomers.
How It Works
- Download the Template: Gain immediate access to the Excel-based VTGN DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically calculates VistaGen's intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose This Calculator for VistaGen Therapeutics, Inc. (VTGN)?
- User-Friendly Interface: Perfect for both novice and experienced users.
- Customizable Inputs: Adjust parameters easily to suit your analysis needs.
- Real-Time Feedback: Observe immediate updates to VistaGen’s valuation as you change inputs.
- Preloaded Data: Comes with VistaGen’s actual financial information for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Accurately assess VistaGen Therapeutics, Inc.'s (VTGN) fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to biotech companies.
- Consultants: Quickly customize the template for valuation reports tailored to clients in the pharmaceutical sector.
- Entrepreneurs: Acquire insights into financial modeling practices utilized by leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation methodologies in the life sciences industry.
What the Template Contains
- Pre-Filled DCF Model: VistaGen Therapeutics’ (VTGN) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate VistaGen’s (VTGN) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.